Zaltoprofen
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Zaltoprofen: From Pain and Inflammation Management to Rheumatoid Arthritis
One-Sentence Summary
Zaltoprofen is a propionic-acid-class NSAID; specific original approved-indication data was not provided in this evidence pack. The TxGNN model predicts it may be effective for Rheumatoid Arthritis, with 0 clinical trials and 7 publications currently supporting this direction, including a long-term multicentre clinical study.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (no Taiwan/India license or original-indication data provided) |
| Predicted New Indication | Rheumatoid Arthritis |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L2 |
| India Market Status | Not Marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action (MOA) data is not available for this evidence pack (flagged as a High-severity data gap, DG002). Based on the literature included here (PMID 25903196), Zaltoprofen is described as an NSAID already clinically employed for rheumatoid arthritis, osteoarthritis, and other chronic inflammatory pain conditions — so the “new indication” signal largely reflects the drug’s known class-level pharmacology rather than a mechanistically distant repurposing hypothesis.
Mechanistically, Zaltoprofen is a propionic-acid NSAID that inhibits COX-1/COX-2 to reduce prostaglandin synthesis — the classic anti-inflammatory/analgesic mechanism shared across the NSAID class. This is directly relevant to RA joint inflammation pathology. Supporting basic-science work (PMID 12065695) further suggests NSAIDs, including zaltoprofen, may induce apoptosis in RA synovial cells via PPAR-gamma activation, offering a plausible (though not disease-modifying-confirmed) biological rationale beyond symptom control.
A secondary, independently-scored candidate in this evidence pack — tendinitis (rank 9, also L2, “Proceed with Guardrails”) — is supported by a randomized, placebo-controlled, double-blind Phase II RCT (PMID 30738433) in tenosynovial giant cell tumor/tenosynovitis patients. This reinforces that Zaltoprofen’s anti-inflammatory activity translates into real clinical benefit in musculoskeletal inflammatory conditions, lending indirect support to the RA hypothesis. Overall evidence quality is limited by the age of most RA-specific studies (1986–2003) and the absence of any registered NCT trial for this indication.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9704197 | 1998 | Long-term multicentre study | Curr Med Res Opin | Non-comparative study of long-term zaltoprofen treatment in RA; assessed grip strength, ESR, and duration of morning stiffness |
| 9831331 | 1998 | Review | Inflamm Res | Review of COX selectivity across NSAIDs; zaltoprofen showed intermediate COX-2 selectivity, relevant to GI safety in RA management |
| 36170456 | 2022 | Preclinical (arthritis model) | Cutan Ocul Toxicol | Oral zaltoprofen alleviated RA-associated dry-skin symptoms in collagen-induced arthritis mice |
| 25903196 | 2015 | In vitro | Chirality | Confirms zaltoprofen’s established clinical use for RA/OA/chronic inflammatory pain; studied UGT enzyme inhibition and chirality (DDI relevance) |
| 12065695 | 2002 | Basic research | J Pharmacol Exp Ther | NSAIDs including zaltoprofen induce apoptosis in RA synovial cells via PPAR-gamma activation |
| 3566842 | 1986 | Preclinical | Arzneimittel-Forschung | Early pharmacology study: zaltoprofen (CN-100) inhibits rat adjuvant arthritis, comparable to indomethacin/pranoprofen |
| 14739775 | 2003 | Case report (AE) | Arerugi | Case of zaltoprofen-induced aseptic meningitis in a Sjögren’s syndrome patient — safety signal |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The RA hypothesis is backed by a consistent NSAID class mechanism (COX-1/COX-2 inhibition) and a long-term clinical study, plus supportive analogous evidence from a Phase II RCT in a related musculoskeletal inflammatory condition (tendinitis). However, RA-specific evidence is dated, lacks a registered RCT/NCT trial, and the drug has no current Taiwan/India market presence.
To proceed, the following is needed:
- TFDA/local package insert warnings and contraindications (currently a Blocking data gap, DG001 — required before any S1 safety review)
- Confirmed mechanism of action (MOA) data (High-severity data gap, DG002)
- Taiwan/India regulatory and licensing status verification
- Updated, controlled clinical evidence (RCT) specific to rheumatoid arthritis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.